T-Cell Immunotherapies for Treating Breast Cancer

摘要

Breast cancer is the most commonly diagnosed cancer among U.S. women (approximately 28% or more than 1 in 4) with approximately 1 in 8 women expected to develop this malignancy over the course of her lifetime. In 2010, there are an estimated 207,000 newly diagnosed cases of invasive breast cancer resulting in about 39,800 deaths in the United States, a mortality rate higher than all other malignancies, except lung cancer. The 5-year survival rate hovers around 75-90 % for women diagnosed in the early stages with a dismal 15% for late stage breast cancer. While there are now more than 2.5 million breast cancer survivors in the U.S., in part due to better diagnostic and therapeutic efficacies, there is still plenty of room for improvement to reduce the mortality rates. Clearly, this is an important disease for women s health and significant resources are focused on developing novel and more effective treatment options.